
Sarah Pihonak
Examiner (ID: 18955, Phone: (571)270-7710 , Office: P/1627 )
| Most Active Art Unit | 1627 |
| Art Unit(s) | 1627, 1617 |
| Total Applications | 1787 |
| Issued Applications | 959 |
| Pending Applications | 107 |
| Abandoned Applications | 739 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19134592
[patent_doc_number] => 11969501
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-30
[patent_title] => Auris formulations for treating otic diseases and conditions
[patent_app_type] => utility
[patent_app_number] => 17/405990
[patent_app_country] => US
[patent_app_date] => 2021-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 89389
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17405990
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/405990 | Auris formulations for treating otic diseases and conditions | Aug 17, 2021 | Issued |
Array
(
[id] => 20715270
[patent_doc_number] => 12630504
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-05-19
[patent_title] => Phenethylamine derivatives, compositions, and methods of use
[patent_app_type] => utility
[patent_app_number] => 18/041728
[patent_app_country] => US
[patent_app_date] => 2021-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 32971
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18041728
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/041728 | Phenethylamine derivatives, compositions, and methods of use | Aug 17, 2021 | Issued |
Array
(
[id] => 17398006
[patent_doc_number] => 20220040096
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 17/405992
[patent_app_country] => US
[patent_app_date] => 2021-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 89464
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17405992
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/405992 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | Aug 17, 2021 | Abandoned |
Array
(
[id] => 17618952
[patent_doc_number] => 11337979
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-24
[patent_title] => Liquid oral formulations for sildenafil
[patent_app_type] => utility
[patent_app_number] => 17/403355
[patent_app_country] => US
[patent_app_date] => 2021-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16729
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17403355
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/403355 | Liquid oral formulations for sildenafil | Aug 15, 2021 | Issued |
Array
(
[id] => 17726552
[patent_doc_number] => 11382917
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-12
[patent_title] => Liquid oral formulations for tadalafil
[patent_app_type] => utility
[patent_app_number] => 17/403282
[patent_app_country] => US
[patent_app_date] => 2021-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16728
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17403282
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/403282 | Liquid oral formulations for tadalafil | Aug 15, 2021 | Issued |
Array
(
[id] => 17718922
[patent_doc_number] => 20220211641
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/399659
[patent_app_country] => US
[patent_app_date] => 2021-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10623
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17399659
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/399659 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE | Aug 10, 2021 | Abandoned |
Array
(
[id] => 18649282
[patent_doc_number] => 20230295068
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => NOVEL CYCLOALKENONE COMPOUND OR SALT THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/040862
[patent_app_country] => US
[patent_app_date] => 2021-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32357
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 185
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040862
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/040862 | NOVEL CYCLOALKENONE COMPOUND OR SALT THEREOF | Aug 5, 2021 | Pending |
Array
(
[id] => 18893669
[patent_doc_number] => 20240009154
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-11
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING CYTOKINE RELEASE SYNDROME
[patent_app_type] => utility
[patent_app_number] => 18/040515
[patent_app_country] => US
[patent_app_date] => 2021-08-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18454
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040515
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/040515 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE RELEASE SYNDROME | Aug 3, 2021 | Pending |
Array
(
[id] => 19896801
[patent_doc_number] => 12274695
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-15
[patent_title] => Pharmaceutical drug therapy for autism
[patent_app_type] => utility
[patent_app_number] => 17/393471
[patent_app_country] => US
[patent_app_date] => 2021-08-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 1129
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17393471
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/393471 | Pharmaceutical drug therapy for autism | Aug 3, 2021 | Issued |
Array
(
[id] => 17290844
[patent_doc_number] => 20210386683
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => COMPOSITIONS AND METHODS RELATING TO RESVERATROL
[patent_app_type] => utility
[patent_app_number] => 17/392060
[patent_app_country] => US
[patent_app_date] => 2021-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10278
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17392060
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/392060 | COMPOSITIONS AND METHODS RELATING TO RESVERATROL | Aug 1, 2021 | Pending |
Array
(
[id] => 17274394
[patent_doc_number] => 20210380592
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => COMPOUND HAVING BENZO SEVEN-MEMBERED RING STRUCTURE, PREPARATION METHOD THEREFOR, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/391241
[patent_app_country] => US
[patent_app_date] => 2021-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 67675
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 656
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17391241
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/391241 | Compound having benzo seven-membered ring structure, preparation method therefor, and use thereof | Aug 1, 2021 | Issued |
Array
(
[id] => 18595959
[patent_doc_number] => 20230270749
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => THERMO-SENSITIVE PERMEATION ENHANCING FORMULATIONS FOR DRUG DELIVERY
[patent_app_type] => utility
[patent_app_number] => 18/019302
[patent_app_country] => US
[patent_app_date] => 2021-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28267
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -70
[patent_words_short_claim] => 168
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019302
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/019302 | THERMO-SENSITIVE PERMEATION ENHANCING FORMULATIONS FOR DRUG DELIVERY | Aug 1, 2021 | Pending |
Array
(
[id] => 17226981
[patent_doc_number] => 20210353537
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => ISOXAZOLINE COMPOSITIONS AND USE THEREOF IN THE PREVENTION OR TREATMENT OF PARASITE INFESTATIONS IN ANIMALS
[patent_app_type] => utility
[patent_app_number] => 17/390296
[patent_app_country] => US
[patent_app_date] => 2021-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7768
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17390296
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/390296 | Isoxazoline compositions and use thereof in the prevention or treatment of parasite infestations in animals | Jul 29, 2021 | Issued |
Array
(
[id] => 18817392
[patent_doc_number] => 20230391732
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-07
[patent_title] => MULTI-EFFICACY PYRAZINE COMPOUND, PREPARATION METHOD AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/018885
[patent_app_country] => US
[patent_app_date] => 2021-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5670
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18018885
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/018885 | MULTI-EFFICACY PYRAZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | Jul 29, 2021 | Abandoned |
Array
(
[id] => 17426721
[patent_doc_number] => 20220054429
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/386914
[patent_app_country] => US
[patent_app_date] => 2021-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8690
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17386914
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/386914 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | Jul 27, 2021 | Abandoned |
Array
(
[id] => 18910297
[patent_doc_number] => 11873266
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-16
[patent_title] => Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke
[patent_app_type] => utility
[patent_app_number] => 17/443361
[patent_app_country] => US
[patent_app_date] => 2021-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 18678
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17443361
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/443361 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | Jul 25, 2021 | Issued |
Array
(
[id] => 18208977
[patent_doc_number] => 20230055237
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
[patent_app_type] => utility
[patent_app_number] => 17/383797
[patent_app_country] => US
[patent_app_date] => 2021-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51434
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17383797
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/383797 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | Jul 22, 2021 | Abandoned |
Array
(
[id] => 18769478
[patent_doc_number] => 20230364244
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY
[patent_app_type] => utility
[patent_app_number] => 18/016262
[patent_app_country] => US
[patent_app_date] => 2021-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18159
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18016262
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/016262 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY | Jul 15, 2021 | Pending |
Array
(
[id] => 18162711
[patent_doc_number] => 20230029304
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => Method of Treating Acute Exacerbation of Schizophrenia with Long-Acting Injectable Depot Composition
[patent_app_type] => utility
[patent_app_number] => 17/377640
[patent_app_country] => US
[patent_app_date] => 2021-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18205
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17377640
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/377640 | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition | Jul 15, 2021 | Issued |
Array
(
[id] => 17198603
[patent_doc_number] => 20210338697
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => LYSOPHOSPHATIDYLCHOLINE COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/370703
[patent_app_country] => US
[patent_app_date] => 2021-07-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19306
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17370703
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/370703 | Lysophosphatidylcholine compositions | Jul 7, 2021 | Issued |